A-101
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Common Wart
Conditions
Common Wart
Trial Timeline
Sep 17, 2018 → Sep 6, 2019
NCT ID
NCT03687372About A-101
A-101 is a phase 3 stage product being developed by Aclaris Therapeutics for Common Wart. The current trial status is completed. This product is registered under clinical trial identifier NCT03687372. Target conditions include Common Wart.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03812510 | Phase 3 | Completed |
| NCT03687372 | Phase 3 | Completed |
| NCT03148691 | Phase 2 | Completed |
| NCT02260180 | Phase 2 | Completed |
Competing Products
20 competing products in Common Wart